Hi @gaurav_681, the company recently completed a slump sale of its API and CRAMS business to Synthimed Labs for ₹1,650 crore on March 18, 2024 , allowing it to reduce debt completely and concentrate on higher-margin formulation products. By selling this segment, the Company paid off almost all of its loan and NCD. So now as on 31 March 2024, the Company is very light on debt and have huge cash reserve for further expansion in formulation business. The book value as on 31 March 2024 is INR 158. It indicates that it is trading at lower price of its genuine book value. Hence good margin of safety is available for all investors in this stock. Seems to be good bet for further any kind of business growth in this Company.
| Subscribe To Our Free Newsletter |
